Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

MyoKardia  (Stock symbol: MYOK ) Acquired by Bristol Myers Squibb (2020 $ 13,100,000,000 )

1000 Sierra Point Parkway
Brisbane, CA 94005
USA
(650) 741-0900
Website Company Summary Management Team
Management

CEO: Tassos Gianakakos (10/30/2013)
General Management: Joseph Lambing (3/31/2014) ; Robert S McDowell (7/31/2012) ; Marc Semigran (12/31/2016)
Finance: Taylor Harris (4/30/2018)
Business Development: Jake Bauer
General Counsel/Legal: Cynthia J Ladd
Board

Outside board: (May no longer be on the board) Mary B Cranston (Pillsbury Winthrop Shaw Pittman Former Sr. Partner) David Meeker (Genzyme EVP) Kimberly Popovits (Genomic Health) Wendy Yarno (Merck & Co. Former SVP HR) Sunil Agarwal (Juno Therapeutics President of R&D) Mark L Perry (Aerovance CEO/President)
Former outside board: Charles J Homcy (Third Rock Ventures) Kevin Starr (Third Rock Venture Partner) Katherine Bowdish (Sanofi VP Global R&D and Head of Sunrise) Eric J Topol (Scripps Translational Science Institute Director)
Company

Business description: MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224. MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
Capital

Rounds: 3
Recent Fundings: May 2015   Aug 2014
Capital raised: 98.0M
Last Round: 46.0M
Ownership: Acquired by Bristol Myers Squibb (2020 $ 13,100,000,000 ) Ipo Filing
Stock Symbol: MYOK
VCs include: Cowen Group;  Third Rock Ventures Casdin Capital ;  Perceptive Life Sciences;  Cormorant Asset Management

Last Tweets


 

Last Mentions


Overview
Record updated: Oct 2020
Sector: Biotech
Year Founded: 2012
Headcount: 301-400 as of Oct 2020
Rounds: 3
Recent Fundings: May 2015   Aug 2014
Capital Raised: 98.0M
Last Round: 46.0M
Ownership: Acquired by Bristol Myers Squibb (2020 $ 13,100,000,000 ) Ipo Filing
Stock Symbol: MYOK